Intralink-Spine Clinical Research Resumes in Australia
Tom Hedman, Ph.D., Founder and Chief Science Officer of Intralink-Spine, Inc. “Our outstanding early data also indicates that 85% of these patients had good or excellent clinical results from the 2-week through 2-year post-treatment time-points."
Intralink-Spine, Inc. Announces ISO-13485 Certification
The certification process included an on-site audit of ILS’s newly constructed GMP manufacturing facility in Lexington, KY.
Intralink-Spine Expands Clinical Studies in Australia
The company reports the Réjuve treatment has the potential to fill the gap between non-operative treatments and surgery.
Intralink-Spine, Inc. Announces Initiation of Clinical Trials in Australia for their Patented Device Réjuve™
3/5/19: According to Hawkins, “We believe the Réjuve medical device, which structurally reinforces the native intervertebral disc itself, is going to be a better treatment option for many patients with low back pain.
Intralink-Spine Expands Clinical Studies To Multiple Sites and Locations
3/27/18: Company has restructured for growth and to better position themselves for a successful CE submission.
New Data for Intralink-Spine’s Réjuve Treatment for Low Back Pain
“We’ve demonstrated the safety of this device, and it has performed as expected. The dramatic pain reduction in these patients correlated with some objective measures: there was an average increase in lumbar range of motion of 9...
